Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;21(5):293-300.
doi: 10.1016/j.smim.2009.05.012.

CD40 and autoimmunity: the dark side of a great activator

Affiliations
Review

CD40 and autoimmunity: the dark side of a great activator

Anna L Peters et al. Semin Immunol. 2009 Oct.

Abstract

CD40 is a tumor necrosis factor receptor superfamily member expressed by immune and non-immune cells. CD40:CD154 interactions mediate T-dependent B cell responses and efficient T cell priming. Thus, CD40 is a likely candidate to play roles in autoimmune diseases in which activated T and B cells cause pathology. Diseases in which CD40 plays a pathogenic role include autoimmune thyroiditis, type 1 diabetes, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. This review discusses the role of CD40:CD154 interaction in human and mouse autoimmunity, human polymorphisms associated with disease incidence, and disrupting CD40:CD154 interactions as an autoimmune therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Potential mechanisms by which CD40:CD154 interactions contribute to autoimmune disease
CD40 signaling may potentially contribute to autoimmune disease in several ways. 1) At the level of T cell selection in the thymus, potentially allowing autoreactive T cell clones to escape deletion. 2) In the secondary lymphoid organs, where T cells are primed by B cells or other APC. 3) Within the target tissue, where CD40 signaling leads to production of pro-inflammatory cytokines and chemokines which contribute to tissue destruction and inflammatory cell influx.

References

    1. Bishop GA, Moore CR, Xie P, Stunz LL, Kraus ZJ. TRAF proteins in CD40 signaling. Adv Exp Biol Med. 2007;597:131–51. - PubMed
    1. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58(1):4–43. - PMC - PubMed
    1. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, et al. Abnormal GC reactions in SLE demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003;112(10):1506–20. - PMC - PubMed
    1. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40L on monocytes from patients with SLE. Clin Immunol. 2002;103(1):54–62. - PubMed
    1. Bishop GA. The multifaceted roles of TRAFs in the regulation of B cell function. Nat Rev Immunol. 2004;4(Oct):775–86. - PubMed